Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Algorae Pharmaceuticals Limited (ASX:1AI)
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Hainsworth
Date of last notice	30 September 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect 1
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**Indirect 1** Union Square Capital Pty Ltd <Endeavor A/C> **Indirect 2** Cathedral Estate Pty Ltd <Cathedral Super Fund>
Date of change	11 November 2026

No. of securities held prior to change	**Direct** (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 1** Union Square Capital Pty Ltd <Endeavor A/C>, an entity in which Mr Hainsworth is a director and controlling shareholder: (a) Nil **Indirect 2** Cathedral Estate Pty Ltd <Cathedral Super Fund>, an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Class	Performance Rights
Number acquired	**Indirect 1** 30,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	**Direct** (a) 20,000,000 fully paid ordinary shares; (b) 20,000,000 performance rights (AGM 2024); (c) 30,000,000 performance rights (AGM 2025); and (d) 4,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 1** Union Square Capital Pty Ltd <Endeavor A/C>, an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 30,000,000 performance rights (AGM 2026). **Indirect 2** Cathedral Estate Pty Ltd <Cathedral Super Fund>, an entity in which Mr Hainsworth is a director and controlling shareholder: (a) 5,937,500 fully paid ordinary shares; and (b) 1,125,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

+ See chapter 19 for defined terms.

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Algorae Pharmaceuticals Limited (ASX:1AI)
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Gulland
Date of last notice	12 March 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect 2
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**Indirect 1** Mrs Rachelle Gulland **Indirect 2** Gull Health Pty Ltd <Gulland Family A/C>
Date of change	11 November 2026

No. of securities held prior to change	**Indirect 1** Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 2** Gull Health Pty Ltd <Gulland Family A/C>, an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; and (c) 42,000,000 performance rights.
Class	Performance Rights
Number acquired	**Indirect 2** 30,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	**Indirect 1** Mrs Rachelle Gulland, spouse of Mr David Gulland: (a) 3,279,333 fully paid ordinary shares; and (b) 655,866 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 2** Gull Health Pty Ltd <Gulland Family A/C>, an entity in which Mr Gulland is a director and controlling shareholder: (a) 1,666,667 fully paid ordinary shares; (b) 15,000,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029; (c) 42,000,000 performance rights; and (d) 30,000,000 performance rights (2026 AGM).

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Algorae Pharmaceuticals Limited (ASX:1AI)
ABN	14 104 028 042

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Troy Valentine
Date of last notice	21 July 2026

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	**Indirect 1** Valplan Pty Ltd <Troy R Valentine Fam S/F A/C> **Indirect 2** Cityside Investments Pty Ltd **Indirect 3** Alignment Capital Pty Ltd
Date of change	11 November 2026

No. of securities held prior to change	**Direct** (a) Nil. **Indirect 1** Valplan Pty Ltd <Troy R Valentine Fam S/F A/C>, an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 2** Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 3** Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Class	Performance Rights
Number acquired	**Direct** 30,000,000
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	**Direct** (a) 30,000,000 performance rights (2026 AGM). **Indirect 1** Valplan Pty Ltd <Troy R Valentine Fam S/F A/C>, an entity which Mr Valentine has an equitable interest in: (a) 15,000,000 fully paid ordinary shares; and (b) 4,960,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 2** Cityside Investments Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 4,150,000 fully paid ordinary shares; and (b) 1,030,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029. **Indirect 3** Alignment Capital Pty Ltd, an entity which Mr Valentine has an equitable interest in: (a) 20,500,000 fully paid ordinary shares; and (b) 4,100,000 unlisted options, each with an exercise price of $0.014 and expiring on 1 December 2029.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Performance Rights following shareholder approval at the Annual General Meeting held on 5 November 2026.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.